Indonesia’s Bio Farma Gains Boost From Germany’s Artes Biotechnology To Expand Vaccines Output

Bio Farma says new technology will help expand vaccines production and work on a hepatitis B vaccine as the country moves to launch a phased universal health care insurance program next year.

JAKARTA – Indonesia plants to boost output of vaccines by nearly 18% to 2 billion doses in 2014 with state-owned Bio Farma looking to build capacity with new technology ahead of the launch of universal health care insurance and to increase exports under its World Health Organization prequalified status.

Indonesia’s vaccine program benefits from a large population and the ability to export to keep production facilities running steadily; there...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Focus On Asia

More from Scrip

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By 

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By 

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.